OPKO Health’s (OPK) Outperform Rating Reiterated at Barrington Research

OPKO Health (NASDAQ:OPK)‘s stock had its “outperform” rating reiterated by analysts at Barrington Research in a note issued to investors on Wednesday,Benzinga reports. They presently have a $2.25 target price on the biotechnology company’s stock. Barrington Research’s price objective would indicate a potential upside of 25.00% from the stock’s current price.

Several other equities research analysts have also commented on the stock. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a report on Monday, March 3rd. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd.

OPKO Health Stock Down 2.2 %

Shares of NASDAQ:OPK opened at $1.80 on Wednesday. The business’s 50 day moving average is $1.60 and its 200 day moving average is $1.56. The stock has a market cap of $1.21 billion, a P/E ratio of -9.47 and a beta of 1.70. OPKO Health has a 52-week low of $0.86 and a 52-week high of $2.04. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.09. The firm had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. Sell-side analysts predict that OPKO Health will post -0.25 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost bought 150,000 shares of the stock in a transaction on Friday, January 17th. The stock was bought at an average cost of $1.47 per share, for a total transaction of $220,500.00. Following the completion of the purchase, the chief executive officer now directly owns 213,186,477 shares in the company, valued at approximately $313,384,121.19. The trade was a 0.07 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders bought 889,971 shares of company stock worth $1,344,442. 47.26% of the stock is owned by corporate insiders.

Institutional Trading of OPKO Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC increased its position in OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 11,089 shares in the last quarter. Orion Portfolio Solutions LLC purchased a new stake in shares of OPKO Health during the third quarter worth about $45,000. Cibc World Markets Corp acquired a new position in shares of OPKO Health during the fourth quarter valued at about $45,000. Zacks Investment Management purchased a new position in shares of OPKO Health in the 4th quarter valued at approximately $49,000. Finally, Ieq Capital LLC acquired a new stake in OPKO Health in the 4th quarter worth approximately $52,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.